The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGF) targeting angiogenesis inhibitors; A reviewESKENS, Ferry A. L. M; VERWEIJ, Jaap.European journal of cancer (1990). 2006, Vol 42, Num 18, pp 3127-3139, issn 0959-8049, 13 p.Article

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer : Where does it fit?ESKENS, Ferry A. L. M; SLEIJFER, Stefan.European journal of cancer (1990). 2008, Vol 44, Num 16, pp 2350-2356, issn 0959-8049, 7 p.Article

Clinical trial design for target specific anticancer agentsHOEKSTRA, Ronald; VERWEIJ, Jaap; ESKENS, Ferry A. L. M et al.Investigational new drugs. 2003, Vol 21, Num 2, pp 243-250, issn 0167-6997, 8 p.Article

Differentiation and definition of vascular-targeted therapiesSIEMANN, Dietmar W; BIBBY, Michael C; DARK, Graham G et al.Clinical cancer research. 2005, Vol 11, Num 2, pp 416-420, issn 1078-0432, 5 p., 1Article

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumorsSOEPENBERG, Otto; DUMEZ, Herlinde; SPARREBOOM, Alex et al.Journal of clinical oncology. 2005, Vol 23, Num 4, pp 889-898, issn 0732-183X, 10 p.Article

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaJONES, Robert J; HAWKINS, Robert E; EATOCK, Martin M et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 435-441, issn 0344-5704, 7 p.Article

Phase i pharmacokinetic, food effect, and pharmacogenetic study of oral Irinotecan given as semisolid matrix capsules in patients with solid tumorsSOEPENBERG, Otto; DUMEZ, Herlinde; LEFEBVRE, Patricia et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1504-1511, issn 1078-0432, 8 p.Article

Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerVAN ZUYLEN, Lia; BRIDGEWATER, John; LEDERMANN, Jonathan A et al.Clinical cancer research. 2004, Vol 10, Num 6, pp 1949-1955, issn 1078-0432, 7 p.Article

Phase I Dose Escalation Study of Telatiiaib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and β-Kit, in Patients With Advanced or Metastatic Solid TumorsESKENS, Ferry A. L. M; STEEGHS, Neeltje; RAJAGOPALAN, Prabhu et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4169-4176, issn 0732-183X, 8 p.Article

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid TumorsSTEEGHS, Neeltje; ESKENS, Ferry A. L. M; LAFFRANCHI, Bernard et al.Journal of clinical oncology. 2009, Vol 27, Num 30, pp 5094-5101, issn 0732-183X, 8 p.Article

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesHOEKSTRA, Ronald; DUMEZ, Herlinde; FIDLER, Isaiah J et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6908-6915, issn 1078-0432, 8 p., 1Article

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (cgs27023A), in patients with advanced solid cancerLEVITT, Nicola C; ESKENS, Ferry A. L. M; NAKAJIMA, Motowo et al.Clinical cancer research. 2001, Vol 7, Num 7, pp 1912-1922, issn 1078-0432Article

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsMARSHALL, John; HWANG, Jimmy; ESKENS, Ferry A. L. M et al.Investigational new drugs. 2013, Vol 31, Num 2, pp 399-408, issn 0167-6997, 10 p.Article

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I StudyMOM, Constantijne H; VERWEIJ, Jaap; OLDENHUIS, Corina N. A. M et al.Clinical cancer research (Print). 2009, Vol 15, Num 17, pp 5584-5590, issn 1078-0432, 7 p.Article

Phase I and pharmacokinetic study of DE-310 in Patients with advanced solid tumorsSOEPENBERG, Otto; DE JONGE, Maja J. A; SPARREBOOM, Alex et al.Clinical cancer research. 2005, Vol 11, Num 2, pp 703-711, issn 1078-0432, 9 p., 1Article

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondm-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerHOEKSTRA, Ronald; DE VOS, Filip Y. F. L; DE VRIES, Elisabeth G. E et al.Journal of clinical oncology. 2005, Vol 23, Num 22, pp 5188-5197, issn 0732-183X, 10 p.Article

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsESKENS, Ferry A. L. M; AWADA, Ahmad; PICCART, Martine et al.Journal of clinical oncology. 2001, Vol 19, Num 4, pp 1167-1175, issn 0732-183XArticle

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid TumorsESKENS, Ferry A. L. M; RAMOS, Francisco J; TABERNERO, Josep et al.Clinical cancer research (Print). 2013, Vol 19, Num 22, pp 6296-6304, issn 1078-0432, 9 p.Article

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid TumorsESKENS, Ferry A. L. M; DE JONGE, Maja J. A; VERWEIJ, Jaap et al.Clinical cancer research (Print). 2011, Vol 17, Num 22, pp 7156-7163, issn 1078-0432, 8 p.Article

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trialKONINGS, Inge R. H. M; VAN DER GAAST, A; VAN DER WIJK, Lidemarie J et al.European journal of cancer (1990). 2010, Vol 46, Num 18, pp 3200-3204, issn 0959-8049, 5 p.Article

A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancerPOLEE, Marco B; SPARREBOOM, Alex; ESKENS, Ferry A. L. M et al.Clinical cancer research. 2004, Vol 10, Num 6, pp 1928-1934, issn 1078-0432, 7 p.Article

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumorsMACKAY, Helen J; HOEKSTRA, Ronald; ESKENS, Ferry A. L. M et al.Clinical cancer research. 2004, Vol 10, Num 8, pp 2636-2644, issn 1078-0432, 9 p.Article